A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-ne...

• Pays France
• Organes Sein
• Spécialités Thérapies Ciblées, Hormonothérapie

Randomizovaná, multicentrická, dvojitě slepá ověřovací studie k posouzení účinku opakovaných infúzí přípravku AIN457 (10mg/kg) oproti placebu na aktivitu onemocnění měřenou MRI scany po dobu 24. týdnů u pacientů s recidivující-remitující roztroušenou sklerózou To determine the effect of AIN457 (10 mg/kg i.v.) administered week 0, 2, 4, 8, 12, 16 and 20 compared to placebo on the number of combined unique active lesions (CUAL) observed on brain MRI scans per...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab • During dose escalation, to determine the MTD of LBH589 that can be combined with trastuzumab, in patients with HER2-positive MBC whose disease has progressed on or after trastuzumab: Arm 1 - Determi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303 To evaluate the safety profile of tobramycin inhalation powder after modifications in the manufacturing process (TIPnew) for the treatment of infections with P.aeruginosa in subjects suffering from cy...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus in de novo renal transplant recipients The primary objective of the study is to demonstrate that in de novo renal transplant patients, at least one of the AEB071 treatment regimens is not inferior to the control treatment (myfortic® + tacr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude CLDK378X2103 ; étude de phase 1, en escalade de dose, évaluant la tolérance et l’efficacité du ceritinib (LDK378), un inhibiteur de ALK, chez des enfants ayant un cancer présentant une altération génétique d’ALK. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] CLDK378X2103 - A phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

• Pays France
• Organes Tout Cancer
• Spécialités Thérapies Ciblées

A study evaluating if the addition of MCS110 increases the efficacy of chemotherapy in women with disseminated breast cancer that is not dependent on hormones To assess the anti-tumor activity of MCS110 combined with carboplatin/gemcitabine (carbo/gem) compared to carbo/gem alone.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD To determine the effect of 50 µg NVA237 compared with matching placebo inhaled once daily on exercise tolerance as measured by exercise endurance time during a sub-maximal constant-load cycle ergometr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%. 52 week extension to a multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11% To demonstrate the efficacy of LAF237 in patients with type 2 diabetes with HbA1c 9- 11% by testing the hypothesis that the HbA1c reduction with LAF237 50 mg BID is superior to that with LAF 237 50 mg...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 6 months, multicenter study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis To evaluate the effect of an individualized patient support program vs. a standard patient support program on treatment satisfaction, measured by a treatment satisfaction questionnaire (TSQM-9) in Fin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune